Drugs / EuCorVac-19
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04783311 | Feb → Oct 2021 | COVID-19 | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05572879 | Oct 2022 → Jun 2023 | COVID-19 | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05603052 | Jul 2022 → Jan 2024 | COVID-19 | EuBiologics Co.,Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-02-25 | EuBiologics Co.,Ltd | Regulatory COVID-19 vaccine developed by UB startup approved for human trials eubiologics.com ↗
The South Korean Ministry of Food and Drug Safety approved a combined phase 1 and 2 clinical trial in January, after generating strong immune responses in animal models. |
| 2021-01-22 | EuBiologics Co.,Ltd | Regulatory EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of EuCorVac-19 in Korea eubiologics.com ↗
EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I/II clinical trial of a COVID-19 vaccine candidate EuCorVac-19 in Korea, immediately entering into the Phase I trial. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-02-25 | EuBiologics Co.,Ltd | COVID-19 vaccine developed by UB startup approved for human trials eubiologics.com ↗ |
| 2021-01-22 | EuBiologics Co.,Ltd | EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of EuCorVac-19 in Korea eubiologics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EuCorVac-19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04783311 ↗ |
| Known as | ECV19 | “EuCorVac-19 (ECV19) is a recombinant protein nanoparticle vaccine that displays the SARS-CoV-2 receptor-binding domain (RBD) on immunogenic nanoliposomes.” PMID 36447243 ↗ Nov 20221“EuCorVac-19 (ECV-19) is a recombinant receptor binding domain (RBD) COVID-19 vaccine” PMID 39318203 ↗ Sep 2024 |
| Modality | Vaccine | “EuCorVac-19 (ECV19) is a recombinant protein nanoparticle vaccine that displays the SARS-CoV-2 receptor-binding domain (RBD) on immunogenic nanoliposomes.” PMID 36447243 ↗ Nov 2022 |
| Route | Intramuscular | “vaccinated intramuscularly on day 0 and day 21” PMID 36447243 ↗ Nov 2022 |